Overview

Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers

Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, open label, randomized, crossover trial to investigate the relative bioavailability of tepotinib in healthy volunteers. Twenty-four volunteers will be randomized to one of the two treatment sequences: Sequence A: test, reference, Sequence B: reference, test. The reference treatment refers to the current Phase II film-coated tablet (5 * 100 milligram (mg) tepotinib film-coated tablets) and the test treatment to the new Phase III film-coated tablet (1 * 500 mg film-coated tepotinib tablet).
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Treatments:
Tepotinib